New hope for hepatitis c: experimental drug combo shows promise
NCT ID NCT01753557
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 3 trial tested an experimental drug called MP-424, combined with two standard hepatitis C medications (pegylated interferon and ribavirin), in 54 adults with genotype 1 hepatitis C. Participants were either new to treatment or had relapsed after previous therapy. The main goal was to see if the virus stayed undetectable 24 weeks after treatment ended (sustained viral response).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MP-424 (an experimental antiviral drug) combined with pegylated interferon alfa-2a and ribavirin
- What this could lead to
- If successful, this combination could offer a new treatment option for people with genotype 1 hepatitis C who have not been treated before or who relapsed after prior therapy.
- What could go wrong
- This is a small, completed Phase 3 trial with only 54 participants, so results may not apply to everyone. The regimen includes interferon, which can cause significant side effects like flu-like symptoms and depression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C (CHC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Toranomon Hospital
Kawasaki, Takatsu-ku, 213-8587, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.